Comparison
Methylene Blue vs Semaglutide
Side-by-side of Methylene Blue and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Methylene Blue | Semaglutide |
|---|---|---|
| Category | pharmaceutical | pharmaceutical |
| Also known as | Methylthioninium chloride, Provayblue, tetramethylthionine chloride | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 5.5 | 168 |
| Typical dose (mg) ↗ | 70 | 2.4 |
| Dosing frequency | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia | weekly (SC); daily (oral Rybelsus) |
| Routes | oral, intravenous | subcutaneous, oral |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 1.5 | 72 |
| Molecular weight | 319.85 | 4113.58 |
| Molecular formula | C16H18ClN3S | - |
| Mechanism | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled | Prescription only (FDA-approved, EMA-approved) |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled in the US | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Contraindicated | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 61-73-4 | 910463-68-2 |
| PubChem CID | 6099 | 56843331 |
| Wikidata | Q409021 | Q27089394 |
Safety profile
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Semaglutide is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Methylene Blue.
- → If your priority is mitochondrial function, pick Methylene Blue.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: Methylene Blue is contraindicated in pregnancy; Semaglutide is the safer pick if that applies.
Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semaglutide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Methylene Blue and Semaglutide?
Methylene Blue and Semaglutide differ in category (pharmaceutical vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Methylene Blue or Semaglutide?
Methylene Blue half-life is 5.5 hours; Semaglutide half-life is 168 hours.
Can you stack Methylene Blue with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper